Amphastar Pharmaceuticals AMPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $79.23M-44.1% | $98.09M-38.5% | $111.63M-29.2% | $134.71M-19.1% | $141.63M-8.4% | ||
| $32.36M+12.3% | $31.65M+12.0% | $30.83M+11.6% | $30.19M+12.4% | $28.8M+11.8% | ||
| $28.16M+10.9% | $27.28M+11.9% | $26.7M+14.3% | $26M+16.1% | $25.4M+18.2% | ||
| $3.35M-28.1% | $3.36M-44.4% | $3.21M-60.9% | $3.07M-75.8% | $4.67M-65.4% | ||
| -$41K— | -$39K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $67.71M— | $69.91M— | ||
| -$12.56M-122% | -$4.56M-107% | $40.2M— | $39.51M— | $58.09M— | ||
| —— | —— | $13.6M+2.0% | $16.38M+408% | $11.38M+263% | ||
| $25.08M+1.2% | $25.05M+1.3% | $24.96M+1.0% | $24.87M+0.6% | $24.79M+32.2% | ||
| $7.05M+45.2% | $6.51M+53.5% | $6.09M+53.2% | $5.48M+40.8% | $4.86M+27.2% | ||
| $168.88M-12.6% | $156.12M-26.8% | $152.28M-26.9% | $159.66M-24.9% | $193.17M-2.6% | ||
| $33.69M-21.5% | $34.88M-15.0% | $39.02M+2.5% | $47.47M+37.7% | $42.95M+14.6% | ||
| -$97.55M+24.8% | -$70.33M+43.7% | -$45.44M+76.4% | -$60.41M+68.0% | -$129.69M+79.3% | ||
| $94.08M— | $75.59M— | $97.07M— | $127.18M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $214K-97.4% | $223K-97.3% | $234K-99.6% | $231K-99.9% | $8.2M-97.4% | ||
| —— | $687K— | —— | —— | —— | ||
| -$83.13M-1.5% | -$67.43M+16.7% | -$82.89M— | -$101.36M— | -$81.88M— | ||
| —— | —— | —— | $186K+147% | $25K+106% | ||
| —— | —— | —— | —— | —— | ||
| $22.93M-11.0% | $23.22M-13.4% | $23.56M-15.5% | $24.62M-14.1% | $25.76M+3.2% | ||
| $19.5M-49.8% | $22.71M-43.4% | $33.41M-56.0% | $45.47M-29.6% | $38.85M-20.7% | ||
| —— | —— | —— | —— | —— | ||
| $25.08M+1.2% | $25.05M+1.3% | $24.96M+1.0% | $24.87M+0.6% | $24.79M+32.2% | ||
| $32.36M+12.3% | $31.65M+12.0% | $30.83M+11.6% | $30.19M+12.4% | $28.8M+11.8% | ||
| -$41K— | -$39K— | —— | —— | —— | ||
| —— | —— | —— | $1.4M-91.0% | -$9.31M-261% | ||
| —— | —— | $13.6M+2.0% | $16.38M+408% | $11.38M+263% | ||
| $7.05M+45.2% | $6.51M+53.5% | $6.09M+53.2% | $5.48M+40.8% | $4.86M+27.2% | ||
| -$6.27M-76.3% | -$5.61M-49.6% | -$4.84M-27.7% | -$4.21M-12.8% | -$3.56M+3.2% | ||
| —— | $687K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.28M+34.6% | $4.36M+5.9% | $5.39M— | $4.86M— | $3.18M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $135.19M-10.0% | $121.23M-29.7% | $113.26M-33.4% | $112.19M-37.0% | $150.23M-6.7% | ||
| $135.19M-10.0% | $121.23M-29.7% | $113.26M-33.4% | $112.19M-37.0% | $150.23M-6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amphastar Pharmaceuticals generate?
- Amphastar Pharmaceuticals (AMPH) generated $168.9M in operating cash flow over the trailing twelve months.
- What is Amphastar Pharmaceuticals's free cash flow?
- After $33.7M of capital expenditures, Amphastar Pharmaceuticals's free cash flow was $135.2M over the trailing twelve months, down 10.0% year over year.
- Where does Amphastar Pharmaceuticals's cash flow data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
